Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene expression in breast cancer.

Virginia G Kaklamani1, William J Gradishar

  • 1Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine of Northwestern University, 676 North St. Clair Street, Suite 850, Chicago, IL 60611, USA.

Current Treatment Options in Oncology
|February 4, 2006
PubMed
Summary

Breast cancer is not monolithic; gene expression profiles define subtypes with distinct prognoses. Gene assays like Oncotype DX show promise for personalized breast cancer treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma-cfDNA of advanced breast cancer patients: A feasibility proof-of-concept study.

Molecular oncology·2026
Same author

The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.

Ecancermedicalscience·2026
Same author

Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic value.

Science translational medicine·2026
Same author

Functional dysconnectivity in breast cancer patients undergoing hormone therapy.

Journal of clinical and experimental neuropsychology·2026
Same author

USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I.

The Journal of clinical investigation·2025

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Breast cancer heterogeneity necessitates subtype classification for tailored treatment.
  • Gene expression profiling reveals distinct breast cancer subtypes (basal, ERBB2+, luminal A/B/C).
  • Subtypes exhibit differential clinical outcomes, impacting prognosis and treatment response.

Purpose of the Study:

  • To characterize breast cancer subtypes based on gene expression.
  • To evaluate the predictive value of gene expression assays for clinical outcome and therapy response.
  • To highlight the future role of genetic tumor characteristics in guiding clinical decisions.

Main Methods:

  • Gene microarrays used for characterizing breast cancer subtypes.
  • Development of gene expression assays (e.g., 21-gene assay, 70-gene assay) for outcome prediction.

Related Experiment Videos

  • Planned prospective clinical trials to validate these predictive tools.

    • Main Results:

    • Identification of basal, ERBB2+, and luminal subtypes with distinct gene expression patterns.
    • Association of specific subtypes with prognosis (basal/ERBB2+ worse, luminal A better).
    • Demonstrated ability of gene assays to predict clinical outcome and therapy response.

    Conclusions:

    • Breast cancer subtypes possess unique genetic signatures and clinical behaviors.
    • Gene expression assays offer powerful tools for predicting patient outcomes and guiding treatment.
    • Future breast cancer management will increasingly rely on genetic tumor profiling for personalized therapy.